Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 4.75M | 10.80M | 9.11M | 6.95M | 5.82M |
Gross Profit | 2.04M | 4.36M | 4.05M | 3.42M | 3.70M |
EBITDA | -994.77K | -6.60M | -1.80M | -1.72M | -3.90M |
Net Income | -1.24M | -7.49M | -2.67M | -3.65M | -3.39M |
Balance Sheet | |||||
Total Assets | 4.10M | 6.19M | 11.11M | 12.92M | 13.29M |
Cash, Cash Equivalents and Short-Term Investments | 395.52K | 1.62M | 2.57M | 3.28M | 6.73M |
Total Debt | 848.05K | 772.64K | 654.33K | 1.76M | 1.43M |
Total Liabilities | 2.28M | 3.48M | 2.22M | 4.64M | 2.86M |
Stockholders Equity | 1.83M | 2.71M | 8.90M | 8.29M | 10.43M |
Cash Flow | |||||
Free Cash Flow | -1.58M | -1.84M | -1.83M | -2.59M | -4.19M |
Operating Cash Flow | -1.58M | -1.74M | -1.78M | -2.55M | -4.17M |
Investing Cash Flow | 0.00 | -197.90K | -1.51M | -968.20K | 477.53K |
Financing Cash Flow | 345.41K | 993.72K | 2.56M | 73.31K | 3.50M |
Anagenics Limited reported a significant improvement in operating cash flows for the quarter ended June 30, 2025, attributed to a successful business restructuring. The company’s Flouf Factor Growth Tonic has performed well, exceeding sales expectations and potentially generating higher royalties in FY2026. Anagenics is also in discussions with Roquefort Therapeutics regarding midkine antibody licensing. The company believes it has sufficient funds to support operations for the next two quarters without additional equity funding.
Anagenics Limited has reported strong performance for Bouf Haircare, a brand developed using its proprietary technology and launched by York Street Brands. Following its successful launch, Bouf Haircare is projected to generate $2.3 million in sales in its first quarter, with expectations to reach $9 million in its first year, surpassing initial forecasts. This success underscores Anagenics’ effective licensing model and the potential for increased profitability through royalty streams, especially with possible international expansion. The launch also highlights York Street Brands’ capability in bringing innovative products to market, further solidifying Anagenics’ position in the industry.
Anagenics Limited has announced the successful launch of Bouf, a new haircare brand by York Street Brands, which utilizes Anagenics’ proprietary hair regrowth technology. The launch, which has already achieved significant sales, underscores the strength of Anagenics’ licensing model and the potential for increased profitability through royalty streams. Bouf’s success also highlights York Street Brands’ capability in bringing innovative products to market, with the potential for global expansion.
Anagenics Limited announced a change in the director’s interest, with Alexander Beard acquiring an additional 55,564 fully paid ordinary shares through an on-market purchase. This acquisition reflects a slight increase in Beard’s indirect shareholding, indicating a potential vote of confidence in the company’s future prospects and stability.
Anagenics Limited has announced a change in the director’s interest, specifically concerning Alexander Beard. On May 16, 2025, Beard acquired 55,564 ordinary shares through an on-market purchase, increasing his indirect shareholding to 6,195,100 fully paid ordinary shares. This transaction reflects Beard’s continued investment in the company, potentially signaling confidence in Anagenics’ future prospects.
Anagenics Limited has announced a change in the director’s interest, specifically regarding Alexander Beard’s shareholdings. On May 14, 2025, Beard increased his indirect shareholding by purchasing 226,881 fully paid ordinary shares, bringing his total indirect holdings to 6,139,536 shares. This transaction was conducted through an on-market purchase, reflecting a strategic move by the director to increase his stake in the company.
Anagenics Limited has announced a change in the director’s interest, specifically regarding Alexander Beard’s shareholdings. The company disclosed that Beard has increased his indirect shareholding by purchasing a total of 2,963,488 fully paid ordinary shares over three days, resulting in a new total of 5,912,655 shares held indirectly. This on-market purchase indicates Beard’s continued confidence in the company’s prospects, potentially impacting investor sentiment positively.
Anagenics Limited has announced a change in the director’s interest notice, specifically concerning Alexander Beard. On May 5, 2025, Beard acquired 1,734,067 ordinary shares through an on-market purchase, increasing his indirect shareholding to 2,949,167 fully paid ordinary shares. This transaction signifies a notable increase in Beard’s investment in the company, potentially indicating confidence in Anagenics’ future prospects.